Blood

Using gene editing to create a stronger clotting factor for treating hemophilia B

Updated

Abstract

Over 60% of the target G:C was converted to A:T, significantly increasing FIX activity.

  • Cytosine base editing was used to introduce a gain-of-function variant in blood coagulation factor IX (FIX).
  • The engineered R338Q variant notably enhanced coagulation factor activity.
  • In HEK293 cells with patient-derived F9 variants, increased FIX activity was observed after base editing.
  • Knock-in mice carrying human F9 cDNA also showed an increase in FIX activity following treatment.
  • Lipid nanoparticles containing the base editor mRNA and gRNA further boosted FIX activity in mice.
  • Cytosine base editing for R338Q in FIX may serve as a scalable therapeutic approach for hemophilia B.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Conflict-of-interest disclosure: N.B., Y.K., and T.O. are the holders of the patent for the methodology described in the present study. T.O. received consultation fees from Chugai Pharmaceutical; research grants from Chugai Pharmaceutical, Pfizer, and Novo Nordisk; and speaker honoraria from Chugai Pharmaceutical, Sanofi, Pfizer, Bayer, Daiichi Sankyo, Takeda Pharmaceutical, Novo Nordisk, Fujimoto Pharmaceutical, LSI Medience, and CSL Behring. The remaining authors declare no competing financial interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free